Project Oncology®

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.

Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.

Episodes 1-16 of 196

DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
Project Oncology®
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Lunning, DO, FACP
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
- Ryan Quigley
- David F. McDermott, MD
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
- Aline Fares, MD
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
Project Oncology®
Studying Carboplatin-Paclitaxel + Retifanlimab for Squamous Cell Carcinoma of the Anal Canal
- Charles Turck, PharmD, BCPS, BCCCP
- Richard Kim, MD
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
Project Oncology®
Uncovering Unmet Needs in Squamous Cell Carcinoma of the Anal Canal Care
- Richard Kim, MD
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
- Jorge Nieva, MD
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
Project Oncology®
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery
- Jorge Nieva, MD
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
Project Oncology®
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden
- Jorge Nieva, MD
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Project Oncology®
Early-Onset Endometrial Cancer: Bridging the Gap Between Age and Outcome
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Project Oncology®
Androgen Receptor Emerges as a Marker of Differentiation in Endometrial Cancer
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
Project Oncology®
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study
- Jorge Nieva, MD
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
Project Oncology®
Overall Survival with Neoadjuvant Therapy in HNSCC: Examining Real-World Data
- Vanessa Helou, MD
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Project Oncology®
Stratifying ICI-P Risk in Non-Small Cell Lung Cancer with Genetic and Radiographic Markers
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
Project Oncology®
Predicting Immunotherapy Outcomes in Head and Neck Cancer: The Role of Genetic Signatures
- George Laliotis, MD, MPH, MHA